Lastin Tablets (Lafutidine)

Adult dose

1. Short-term treatment of gastric ulcers: The usual dose is 10mg of lafutidine orally twice daily, in the morning and before bedtime. Clinical trial results for treatment for up to 8 weeks showed that most ulcers healed within 8 weeks, although the healing period may vary among patients. 2. Short-term treatment of duodenal ulcers: The usual dose is 10mg of lafutidine orally twice daily, in the morning and before bedtime. Clinical trial results for treatment for up to 6 weeks showed that most ulcers healed within 6 weeks, although the healing period may vary among patients. 3. Improvement of gastric mucosal lesions in acute and chronic gastritis: The usual dose is 10mg of lafutidine orally once daily before bedtime. Clinical trial results for treatment for up to 2 weeks showed that most lesions healed within 2 weeks, although the healing period may vary among patients. 4. Combination therapy with antibiotics in patients with peptic ulcers infected with Helicobacter pylori: Administer lafutidine 20mg, clarithromycin 500mg, and amoxicillin 1000mg twice daily for 7 days or 14 days. 5. Premedication before anesthesia: The usual dose is 10mg of lafutidine per administration, given twice (before bedtime on the day before surgery and 2 hours before administration of anesthesia on the day of surgery), orally. 6. Treatment of gastroesophageal reflux disease: Administer 10mg of lafutidine per administration, twice daily, orally.

This medicine should not be used in patients with hypersensitivity to any component of this medication. Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Caution is required when administering this drug to patients with a history of drug hypersensitivity, those with liver or kidney dysfunction, dialysis patients, and the elderly. This drug can rarely cause serious allergic reactions such as anaphylaxis or shock; therefore, if symptoms such as facial pallor, decreased blood pressure, or difficulty breathing occur, administration should be stopped immediately and appropriate treatment should be sought. Liver function abnormalities or jaundice may occur; therefore, liver function tests should be performed regularly, and if abnormalities are found, use of the drug should be discontinued. Agranulocytosis or thrombocytopenia may occur, so if symptoms such as sore throat, generalized malaise, or fever emerge, administration should be stopped immediately and medical advice should be sought. Severe blood disorders, convulsions, skin rashes, cardiac problems, etc., have been reported with similar medications, so if unusual symptoms occur, consult a doctor immediately. Gastrointestinal symptoms such as constipation, diarrhea, nausea, vomiting, abdominal bloating, and loss of appetite may occur, while central nervous system symptoms include headaches, insomnia, drowsiness, and dizziness. Elderly patients may have decreased bodily function, so dosing and administration intervals should be adjusted, and they should be closely monitored. Pregnant women or women of childbearing potential should only use this medication if the therapeutic benefit outweighs the risks, as judged by a physician; breastfeeding women should preferably avoid this drug as it may be secreted in breast milk. Safety in children has not yet been established, so caution is advised when using it in pediatric patients. This drug should be kept out of the reach of children, and it should be stored in the original container to maintain quality and prevent misuse. Prolonged use of this medication may mask symptoms of malignant tumors or delay diagnosis, so regular examinations are required if gastric ulcers or malignant tumors are suspected. Dialysis patients may have elevated serum levels of this drug, so it should be initiated cautiously at a low dose.

• Shock
• symptoms of anaphylaxis
• facial pallor
• hypotension
• generalized rash
• dyspnea
• hepatic dysfunction
• jaundice
• agranulocytosis
• pharyngitis

This medication should be stored in a tightly closed container to protect it from air and moisture. A storage temperature between 1 degree and 30 degrees Celsius is recommended.

Appearance

White, round, film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle